| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3274361 | Médecine des Maladies Métaboliques | 2014 | 7 Pages |
Abstract
This study retrospectively assessed, over 12 months, the clinical effectiveness of incretin based therapies (glucagon-like peptide-1 receptor agonists [GLP1-ra]: liraglutide and exenatide; dipeptidylpeptidase IV inhibitors [DPP4-i]) initiated according to the National Institute for Health & Clinical Excellence (NICE) recommendations, among type 2 diabetes patients in Wales, UK. HbA1c level reduction was significantly greater with liraglutide vs. exenatide or DPP4-i. Moreover, weight loss was significantly increased for both liraglutide and exenatide vs. DPP4-i. Patient preference between GLP1-ra and DPP4-i was also studied in a separate prospective study.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
M. Evans, P. McEwan, R. O'Shea, L. George,